Top Markets
#1 Ontology Gas Ontology Gas +46.81%
#2 Verus Coin Verus Coin +22.52%
#3 EXOD EXOD +22.08%
#4 Fake World Assets Fake World Assets +22.08%
#5 ETHGas ETHGas +21.14%
#6 Status Status +17.96%
#7 Geodnet Geodnet +17.50%
#8 The Black Bull The Black Bull +16.80%
#9 Derive Derive +11.99%
#10 Ontology Ontology +11.87%
Coin of the day
Ontology Gas Ontology Gas
Settings
Language
ENGLISH
Currency
USD
Theme
Promore Pharma AB (publ) Promore Pharma AB (publ)

Promore Pharma AB (publ)

PROMO
Rank in Stocks #25506
Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to... Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to advancing peptide-based drug therapies. The company's development pipeline features PXL01, currently undergoing Phase IIa studies for its potential in preventing post-surgical adhesions and scars, mitigating dermal scarring, and aiding hand tendon repair. Another key asset, LL-37, is engaged in Phase IIb clinical trials to address venous leg ulcers, stimulate the healing of persistent wounds, and treat diabetic foot ulcers. Additionally, Promore Pharma has partnered with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. Founded in 2002, the company, formerly known as Lipopeptide AB until its rebranding in January 2017, maintains its headquarters in Solna, Sweden.
Share Price
$1.34
Last synced: 2024-02-14
Market Cap
$48.96M
Change (1 day)
-12.94%
Change (1 year)
0.00%
Country
SE
Trade Promore Pharma AB (publ) (PROMO)

Category

Healthcare
Revenue for Promore Pharma AB (publ) (PROMO)
Revenue in Aug 2026 TTM: 0
According to Promore Pharma AB (publ) latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Promore Pharma AB (publ) from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US